CLINICAL AND BIOLOGICAL EVALUATION OF THE NOVEL CD30/CD16A TETRAVALENT BISPECIFIC ANTIBODY (AFM13) IN RELAPSED OR REFRACTORY CD30‐POSITIVE LYMPHOMA WITH CUTANEOUS PRESENTATION: A BIOMARKER PHASE IB/IIA STUDY (NCT03192202).

Authors :: Sawas, A.
Chen, P.
Vlad, G.
Lipschitz, M.
Abdul‐Hay, M.
Lue, J.
Deng, C.
Amengual, J.E.
Marchi, E.
Shulman, J.
Elgedawe, H.
Shong, M.V.
Khan, K.
Geskin, L.
Rodig, S.J.
O'Connor, O.
Source :: Hematological Oncology; Jun2019 Supplement S2, Vol. 37, p314-316, 3p
Publication Year :: 2019

Subjects :: BISPECIFIC antibodies
CUTANEOUS T-cell lymphoma
LYMPHOMAS
ETIOLOGY of diseases
KILLER cells

Full Text Access

Tools